Articles tagged with Amyotrophic Lateral Sclerosis
A team of researchers from Ritsumeikan University in Japan has elucidated the mechanism behind the liquid-solid phase transition of FUS protein that leads to ALS. They discovered a new therapeutic target, arginine, which suppresses FUS aggregation and could delay ALS progression.
A study investigated the frequency and characteristics of non-motor symptoms in ALS patients, finding over 90% experienced symptoms such as fatigue, pain, and sleep disorders. These symptoms reduced QoL even when motor symptoms were mild, highlighting their importance to consider.
A new study finds that the drug terazosin has shown protective effects on motor neurons in models of motor neuron disease (MND), including zebrafish, mice and stem cell models. Researchers hope to launch a full clinical trial if the drug proves successful in a feasibility study involving 50 patients.
A team of researchers has discovered a protein called NOVA1 that displays pathological characteristics in ALS patients at an early stage. This finding could lead to the development of new therapy concepts and potentially enable early detection of the disease.
Researchers found altered cell-mediated immune function in ALS patients and a novel treatment approach using bone marrow transplants. The study suggests that abnormal CD8 T-cell response contributes to motor neuron degeneration.
Researchers from Mount Sinai found a significant connection between the immune system and amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease. The study analyzed mice and human samples using state-of-the-art technologies, revealing peculiar immune signatures that distinguish different forms of ALS.
A new muscle biopsy test could lead to an earlier diagnosis of amyotrophic lateral sclerosis (ALS), a progressive disease affecting nerve cells in the brain and spinal cord. The test targets transactive response DNA-binding protein 43 (TDP-43) accumulation, which may be a biomarker for early ALS diagnosis.
The JNM Molecular Imaging of Neurodegeneration Supplement provides an overview of molecular imaging techniques in neurodegenerative disorders. The supplement aims to improve early and differential diagnosis, as well as stratify and monitor therapy in these disorders.
Research reveals pridopidine enhances autophagy in ALS model, reducing toxic protein aggregation and promoting neuronal health. The study supports pridopidine's potential as a treatment for neurodegenerative diseases like Huntington's disease and Alzheimer's.
Research on experimental drug NU-9 invents by Northwestern University scientists reveals it is more effective than existing FDA-approved drugs for ALS treatment. NU-9 also repairs the axons of diseased upper motor neurons in ALS mouse model, offering a potential new approach to treating the devastating disease.
The Silence ALS program aims to treat patients with rare genetic forms of ALS using antisense oligonucleotides, potentially delaying disease onset or slowing progression. The initiative focuses on individuals identified through Columbia University's ALS Families Project.
Researchers have found a possible target for ALS treatment in astrocyte abnormalities. Astrocytes, a subtype of cells in the central nervous system, are involved in motor neuron death, leading to muscle weakness and paralysis. The study offers hope for developing new drugs to block this process.
A new brain-computer interface device has been found safe in a small study of people with ALS, allowing participants to communicate through text and perform daily tasks. Researchers have also developed a machine-learning decoder that enables independent computer control without eye tracking.
Researchers have identified a biomarker, TDP-43, detectable in small skin samples of patients with Amyotrophic Lateral Sclerosis (ALS), allowing for potentially easier diagnosis and early detection. The presence of this protein in the skin of ALS patients is associated with an increased number of fibroblasts with disease marks.
A new study aims to slow muscle degeneration in ALS patients by targeting the renin-angiotensin system. Researchers have found that an investigational drug, CAP-1902, reduces inflammation and oxidative stress in models of Duchenne muscular dystrophy.
The Hybrid Assistive Limb (HAL) robot has been shown to improve gait ability in patients with amyotrophic lateral sclerosis (ALS), allowing them to walk longer distances with reduced assistance. The therapy sessions, lasting only 20-40 minutes per day for four weeks, also demonstrated preservation of other vital functions.
A study published in eLife found that measuring changes in immune cell populations may help predict the prognosis of patients with ALS. Certain immune cells were associated with better or worse survival rates, providing new insights into the disease's progression.
Researchers discovered that an inorganic polyphosphate released by nerve cells contributes to the death of motor neurons in people with ALS and frontotemporal dementia. The study found that lowering levels of this toxin may be an innovative therapeutic strategy for diverse types of ALS/FTD.
Scientists successfully revive motor neurons in laboratory experiments, showing promise for ALS treatment. The method uses magnetic field pulses to improve nerve function and transport, with healthy cells remaining unchanged.
The Precision ALS programme aims to provide new insights into Motor Neuron Disease through advanced data-driven prediction models and next-generation data analysis. The project will harness AI to analyse large amounts of data from a multimodal dataset, providing tools for clinical trials based on precision-medicine.
Researchers found that mislocalization of TDP-43 protein alters genetic instructions for UNC13A, providing a possible therapeutic target for treating ALS and FTD. The studies suggest that increasing UNC13A or stathmin 2 levels may prevent neuron death in these diseases.
Researchers discover a genetic mechanism linking ALS and dementia to UNC13A protein corruption, providing hope for new treatments by blocking corrupted instructions. The study found that genetic variants increase the risk of UNC13A mRNA corruption in patients with ALS and FTD.
The ALS Canada Research Program has awarded nine Discovery Grants to investigate critical areas of disease processes and clinical care. The grants will support fundamental laboratory research, biomarker studies, and clinical trials.
A new cloud-based data resource has been developed to help identify new subtypes of amyotrophic lateral sclerosis (ALS), a fatal neurological disorder. The tool, part of the Answer ALS collaborative effort, uses biological and clinical data from over 1,000 patients to better understand the disease.
Researchers at University of Gothenburg and Umeå University discovered a link between blood levels of neurofilaments and ALS diagnosis. Blood tests can differentiate ALS from other diseases, offering new opportunities for screening and measuring neurofilaments.
A new meta-analysis of available literature on ALS disease has identified a group of seven environmental chemicals as correlates with increased risk of developing ALS. Exposure to these chemicals, including BMAA and heavy metals, may be contributing to the disease burden in certain regions.
Researchers developed an experimental drug that silences a faulty FUS gene, potentially treating rare and aggressive forms of ALS. The treatment delayed motor neuron degeneration in mice and showed promise in a patient with FUS-ALS.
Researchers found that astrocytes become pro-inflammatory and lose protective functions in ALS, leading to toxic build-up of glutamate that damages motor neurons. The study also identified distinct molecular patterns in astrocytes associated with different ALS-causing genetic mutations.
A UMass Chan clinical trial demonstrates the safety and efficacy of an antisense oligonucleotide in suppressing mutant C9ORF72, a common cause of familial ALS. The treatment led to reduced levels of neurotoxins and stable or improved ALS functional scores.
Researchers have identified a new molecular component of Amyotrophic Lateral Sclerosis (ALS) pathological aggregates, a circular RNA called circ-Hdgfrp3. This circular RNA plays a crucial role in the formation and progression of ALS, highlighting its potential as a therapeutic target.
A study of 19,000 NFL players found a significantly higher incidence of ALS diagnosis and death among players compared to the U.S. male population.
Researchers have determined the molecular structure of TDP-43 aggregates extracted from human brains, shedding light on its role in neurodegenerative diseases like ALS. The discovery may lead to the development of targeted therapies and diagnostic tests.
A new Northwestern study reveals that brain motor neurons degenerate early in diseases like ALS, sending warning signals and showing defects. Targeting the brain's motor neurons could lead to long-term and effective treatment strategies.
A study published in Molecular Genetics and Metabolism found that riluzole slows the progression of Niemann-Pick disease type C1 by reducing glutamate toxicity, increasing mouse survival by 12%. Researchers believe similar drugs may help slow disease progression in patients with NPC1.
Researchers at Universidad Complutense de Madrid have discovered alterations caused by ALS in the retina, which can be used as biomarkers for diagnosis and treatment monitoring. The study found changes in microglial cells and ganglion cell loss, with modifications evolving over the course of the disease.
A study published in Brain Pathology found elevated levels of tau protein in the brains of people with ALS who carry a mutation in the C9orf72 gene. The researchers also identified new genetic mutations in the tau gene and discovered that the ratio of different forms of tau protein may be an indicator of disease progression.
Researchers at Massachusetts General Hospital discovered that reducing abnormal tau can reverse mitochondrial dysfunction and oxidative stress in ALS. By targeting tau with a specific degrader, the study suggests a promising new treatment strategy for this degenerative disease.
A collaboration led by Scripps Research Institute successfully treated C9 ALS/FTD in mice using a novel RNA-hunting compound that recruits the cell's own virus fighter. The compound eliminated 70% of toxic protein fragments and removed most hallmarks of the disease from patient-derived nerve cells.
A new study suggests that vigorous exercise during leisure time is not associated with an increased risk of developing amyotrophic lateral sclerosis (ALS). However, intense physical activity at work hours was linked to a higher risk, possibly due to repetitive motion or exposure to chemicals. Moderate exercise, even after symptoms begi...
A study published in Cell Metabolism identified a protein called neurturin as crucial for muscle health, improving metabolic rates, motor function and exercise capacity. Mice genetically modified to produce more neurturin had increased resistance to degeneration in neurons associated with ALS.
Researchers at University of Illinois Chicago found a potential direct connection between neurodegenerative diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), glaucoma, and herpesvirus. The study suggests OPTN protein restricts HSV-1 virus spread in cells.
A large epidemiology study found associations between higher HDL and apoA1 levels with a lower risk of ALS. Lower LDL and apoB levels were also linked to decreased risk. These findings may support population screening and preventative therapy for ALS.
A new study from Salk Institute researchers found that a critical threshold of miR-218 levels determines the development of ALS in animal models. The study sheds light on the complex control of gene expression and its implications for treating neurological disorders.
Researchers have identified a novel genetic marker, rs139185008, that distinguishes C9orf72 repeat expansion carriers from non-carriers in large population-based cohorts. This SNP is strongly associated with patients having a clinical diagnosis of FTLD and motor neuron disease ALS.
Researchers at The Francis Crick Institute successfully reversed a key hallmark of motor neurone disease by blocking the activity of an enzyme called VCP. This breakthrough, published in Brain Communications, suggests that the abnormal accumulation of proteins involved in RNA regulation might be a factor contributing to the disease.
A recent study discovered that brain cells cannot maintain the myelin sheath in the absence of the TDP-43 protein. Restoring cholesterol levels has been proposed as a potential therapeutic strategy for neurodegenerative diseases associated with TDP-43. The research found that oligodendrocytes, responsible for producing myelin, have def...
A study published in Science Translational Medicine identified a common cellular defect in ALS that can be treated with an antisense oligonucleotide drug. Researchers found that the accumulation of CHMP7 protein in the nucleus leads to nuclear pore injury and TDP-43 mislocalization, ultimately causing cell death.
A distinctive inflammatory signature has been found in C90RF72 ALS patients, characterized by an increase in pro-inflammatory molecules in serum and cerebrospinal fluid. This finding informs the development of targeted anti-inflammatory therapies for this subgroup of ALS patients.
Researchers identified a new gene, TP73, associated with an increased risk of sporadic ALS. Mutations in this gene have been found to interfere with nerve cell health and lead to abnormal cell differentiation and increased cell death. This discovery provides a potential target for therapy development.
A new study found that networks of nerve cells in the spinal cord called inhibitory interneurons lose connection to motor neurons, which could explain why motor neurons die in ALS. This loss happens before motor neuron death and affects fast-twitch motor neurons first.
Researchers link ALS to a unique genetic mutation affecting lipid metabolism, providing clues for a novel therapy and understanding the disease's progression. The study reveals slower symptom onset and longer survival rates in children compared to adults with ALS.
A revolutionary assistive technology called Earswitch allows people with Motor Neurone Disease (MND) to communicate by tensing a tiny muscle in their ear. The device uses the tensor tympani muscle, which can be controlled voluntarily, and offers a new way for individuals with severe communications restrictions to express themselves.
A new study reveals that protein Rab2 is essential for effective nerve cell signaling in the central nervous system. The researchers found that when Rab2 is absent or dysfunctional, signal molecules accumulate in axons like a traffic jam.
Researchers found that Staufen1 accumulates in brains of patients with neurodegenerative disorders, disrupting normal cellular function. Lowering Staufen1 levels may improve pathology and rid cells of stress granules, a key finding for potential treatment approaches.
Researchers have identified a neuroprotective pathway that sustains the nucleocytoplasmic RAN gradient, suppressing Lou Gehrig's Disease. The LSM12-EPAC1 pathway normalizes abnormal RAN concentration differences, restoring cellular function.
Researchers at Case Western Reserve University have determined the structure of protein fibrils linked to Lou Gehrig's disease and other neurodegenerative disorders. The findings provide clues on how toxic proteins clump and spread between nerve cells in the brain, potentially leading to the development of new treatments.
Researchers at the Francis Crick Institute have identified the key cellular change that leads to harmful astrocytes in amyotrophic lateral sclerosis (ALS). The discovery could lead to new therapies to slow disease progression and is also relevant to other neurodegenerative diseases like Parkinson's and Alzheimer's. Understanding this c...
Researchers have identified a new signaling pathway that regulates the production of RNA-protein complexes in neurons, which are overproduced in neurodegenerative diseases such as ALS and senile dementia. This discovery may lead to better understanding and potential therapeutic options for these conditions.
Scientists at Northwestern University have identified a compound that eliminates degeneration of upper motor neurons in ALS, a neurodegenerative disease. After 60 days of treatment, diseased brain cells regain health and function like healthy control neurons.
Researchers found higher than expected genetic changes in a group of 100 MND patients, suggesting routine genetic testing may be beneficial. The study recommends genetic testing for all MND patients, regardless of family history, to improve disease subclassification and tailored treatments.